Effect of vitamin A on intestinal mucosal injury in pediatric patients receiving hematopoietic stem cell transplantation and chemotherapy: a quasai-randomized trial

Table 2 Incidence and duration of secondary outcomes within 60 days of hematopoietic stem cell transplantation in the two groups of study patients

Outcomes	Study groups		P value
Outcomes	Vitamin A supplementation (n = 15)	Non-vitamin A supplementation (n = 15)	P value
Febrile neutropenia, n (%)	11 (73.3)	11 (73.3)	1
Oral mucositis, n (%)	14 (93.3)	15 (100)	1
Oral mucositis severity grade 3–4, n (%)	6 (40)	9 (60)	0.27
Diarrhea, n (%)	14 (93.3)	14 (93.3)	1
Hemorrhagic cystitis, n (%)	5 (33.3)	5 (33.3)	1
Graft-versus-host disease, n (%)	6 (40)	7 (46.7)	1
Bacterial infection, n (%)	1 (6.7)	2 (13.3)	1
Viral infection, n (%)	10 (66.7)	6 (40)	0.14
Day of neutrophil engraftment, mean days ± SD	14 ± 2.8	14.2 ± 3.9	0.87
Duration of febrile neutropenia^a, days	5 (2–10)	6.5 (1–21)	0.8
Duration of mucositis, mean days ± SD	9 ± 3.8	9 ± 4.7	0.96
Duration of diarrhea^a, days	11.5 (2–44)	15.5 (2–37)	0.42
Duration of need of TPN, days ± SD	13 ± 7.1	11 ± 6.6	0.42
Duration of hospitalization after day 0^a, days	29 (18–83)	24 (15–54)	0.13
Mortality, n (%)	0	2 (13.3)	0.48

ISSN: 1756-0500